Unlike common-law jurisdictions, which often permit foreign companies to conduct regulated pharmaceutical activity through a registered branch with minimal separation from the parent entity, Georgian corporate law draws a sharp functional boundary between its three principal structures for foreign market entry: the branch, the limited liability company, and the representative office. For a foreign pharmaceutical business assessing Georgia as either a distribution hub, a manufacturing base, or a regulatory bridgehead into the Caucasus and Central Asian corridor, the choice of structure determines not only corporate liability exposure but also the ability to hold pharmaceutical licences, employ local regulatory personnel, and maintain VAT registration. This guide sets out the legal and practical differences across all three forms, with specific reference to the requirements that Georgia's pharmaceutical regulatory framework imposes on each.
Before selecting a legal vehicle, gather the following:
This checklist is not a substitute for legal analysis specific to your circumstances. The structure that is optimal for a European manufacturer distributing branded pharmaceuticals in Georgia may be entirely unsuitable for a trading company sourcing Georgian-origin products for re-export.
[CTA: If you are assessing legal structures for pharmaceutical market entry into Georgia, make an enquiry: info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]
Georgian law offers foreign entities three standard vehicles for commercial presence, each governed by the Law of Georgia on Entrepreneurs.
A branch (Georgian: filiali) is a structurally separate subdivision of the foreign legal entity. It is not a separate legal person. The branch registers with the National Agency of the Public Registry (NAPR) and obtains a Georgian identification number, but all obligations and liabilities of the branch remain obligations of the foreign parent. In pharmaceutical terms, this creates a direct exposure pathway: a product liability claim or a regulatory fine levied on the branch is enforceable against the parent's global assets.
A subsidiary — in practice almost always constituted as a limited liability company (ShrP, equivalent to an LLC) — is a separate Georgian legal person. Its liability is ring-fenced to the subscribed capital and the company's own assets. The subsidiary can hold Georgian pharmaceutical product registrations, enter regulatory licensing agreements in its own name, and independently employ staff under Georgian labour law. It is the default structure for foreign companies intending to conduct substantive pharmaceutical operations in Georgia.
A representative office (warmomadgenloba) is also not a separate legal person and, critically, is prohibited from conducting commercial activity. It may carry out market research, liaise with counterparties, support the parent's promotional activities, and maintain a local presence — but it cannot conclude sales contracts, issue invoices in Georgia, or hold pharmaceutical licences. Foreign pharmaceutical companies that operate in Georgia through a representative office while conducting de facto commercial activity risk reclassification by the Revenue Service of the Ministry of Finance, with attendant tax and penalty exposure.
Each structure registers through NAPR, and as a general rule each can be established within one to three business days once documentation is in order, though pharmaceutical-specific licensing from the relevant regulatory authority adds a separate timeline.
The activity type determines which structures are legally viable.
Distribution of registered pharmaceutical products: A subsidiary (LLC) is the standard and preferred vehicle. It can hold the product registration (or act as a registered importer under an authorisation from the foreign registration holder), issue VAT invoices, enter distribution agreements with Georgian wholesalers, and bear employment obligations for regulatory affairs staff. A branch can also conduct distribution but exposes the foreign parent to full liability. A representative office cannot distribute.
Clinical trial support or regulatory liaison only: A representative office is sufficient and avoids the administrative overhead of a full LLC registration. However, the moment the office begins receiving consideration for services or reimbursing expenses that constitute commercial activity, reclassification risk arises. The practical advice is to establish an LLC if any revenue stream — however modest — will be generated locally.
Manufacturing or re-packaging: Georgia's free industrial zones and special economic zones (notably the Kutaisi Free Zone and Poti Free Zone) offer alternative structuring options for manufacturing activity. Within these zones, an LLC or a branch of a foreign entity may operate, but pharmaceutical manufacturers must additionally satisfy Good Manufacturing Practice requirements assessed by the regulatory authority. The representative office form is not viable for manufacturing purposes.
Regional headquarters or holding function: Where a foreign group wishes to use its Georgian presence to coordinate operations across the South Caucasus and Central Asia — including Russia-to-Georgia cross-border supply chains — an LLC offers the greatest structural flexibility. Georgia's territorial tax system means that income earned outside Georgia by a Georgian LLC is, as a general rule, not subject to Georgian corporate income tax, which can make the LLC a tax-efficient regional coordination vehicle. Confirm the specific treaty and statutory position for your home jurisdiction with Georgian counsel before relying on this characterisation.
Note: Pharmaceutical product registrations in Georgia are issued by Georgia's pharmaceutical regulatory authority to the registration holder. Where a branch holds the registration, the registration is in practice contingent on the continued existence of the foreign parent's authorisation in its home jurisdiction. A subsidiary holds the registration independently. Foreign pharmaceutical companies that have experienced regulatory disruption in their home jurisdiction should factor this structural dependency into their choice of entity.
Registering a legal entity with NAPR is a precondition for pharmaceutical activity in Georgia, but it does not, of itself, authorise pharmaceutical operations. A separate regulatory layer applies.
Georgia's pharmaceutical regulatory authority — currently operating under the Ministry of Internally Displaced Persons, Labour, Health and Social Affairs and subject to periodic institutional reorganisation — licenses pharmaceutical manufacturers, importers, wholesalers, and retail pharmacies. The specific licence type required depends on the activity: import and wholesale of medicinal products requires a dedicated licence; retail pharmacy activity requires a separate retail licence; manufacturing requires a manufacturing authorisation with GMP assessment.
The licensing application is made by the Georgian legal person or branch conducting the activity. A representative office cannot hold a licence. The standard documentation for a wholesale import licence includes: proof of legal entity registration, description of storage premises (meeting temperature-controlled warehouse standards for relevant product categories), proof of qualified personnel (a responsible pharmacist or pharmaceutical specialist), and product registration documentation for each product line.
For foreign companies entering Georgia from the post-Soviet space — including companies with existing operations in Russia, Kazakhstan, or Armenia — there is no automatic mutual recognition of pharmaceutical licences or product registrations with Georgia (Georgia is not an EAEU member). Each product must be registered separately under Georgian procedure, which typically involves a technical dossier review by the regulatory authority. Registration timelines vary by product type and review pathway; as a general rule, allow six to eighteen months for a new product registration unless an accelerated procedure is available for the specific category.
A branch or subsidiary conducting import and wholesale activity must additionally register for VAT if the annual turnover of taxable supplies exceeds the statutory threshold under the Georgian Tax Code. At the time of drafting, that threshold is GEL 100,000 per calendar year, though the Tax Code should be checked for any amendments.
[CTA: Firms advising clients on pharmaceutical market entry into Georgia will often need confirmed local counsel before the product registration timeline becomes a live issue. Speak to our team: info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]
Registration of all three structures is processed through NAPR. The process is largely electronic and, for straightforward applications, is among the fastest entity registrations in the region.
For a subsidiary (LLC):
For a branch:
For a representative office: The registration process mirrors that of a branch. The key distinction in the registration documentation is the stated scope of activity — the application must accurately reflect the non-commercial nature of the representative office's functions.
Post-registration steps (all structures):
Registration and licensing are the entry point, not the endpoint.
Annual reporting: A Georgian LLC is required to prepare and file financial statements. For pharmaceutical companies above certain revenue thresholds, an audit by a licensed Georgian auditor may be required. Branches of foreign companies similarly have financial reporting obligations that feed into the parent's consolidated accounts.
Employment and HR: Georgian labour law applies to all employees engaged in Georgia, regardless of entity type. Pharmaceutical companies employing a responsible pharmacist or regulatory affairs specialist should note that certain positions may require Georgian professional qualification recognition.
Regulatory renewals: Pharmaceutical licences are subject to periodic renewal and may require confirmation of continued compliance with storage, personnel, and documentation standards. The regulatory authority conducts inspections; non-compliance can result in suspension or revocation of the licence. A subsidiary retains its licence independently of any changes in the foreign parent's status; a branch does not.
Transfer pricing and related-party transactions: Where a Georgian LLC or branch transacts with its foreign parent or related entities — as is common in pharmaceutical supply chains involving intercompany product supply agreements — the Georgian Tax Code applies transfer pricing rules. Transactions must be at arm's length; documentation requirements apply above defined thresholds.
Trade mark registration: Pharmaceutical brand owners entering Georgia should register their trade marks with the Intellectual Property National Center (Sakpatenti) before commencing promotional activity. Georgia operates a first-to-file trade mark system. Early registration avoids the risk of opportunistic filings by third parties, a risk that has affected foreign pharmaceutical brands in several post-Soviet markets.
For cross-border structures involving both Russia and Georgia — for example, where a Russian entity acts as regional distributor and a Georgian LLC manages South Caucasus and export markets — additional cross-border legal analysis is advisable, covering both the Russian and Georgian sides of the structure. Vetrov & Partners advises on the Russian-law dimension of such arrangements; for the Georgian-law dimension, we collaborate with trusted Georgian counsel.
Q: How long does it take to register a legal entity in Georgia for pharmaceutical activity?
A: Entity registration with NAPR — whether an LLC, branch, or representative office — typically takes one to two business days from the submission of a complete documentation package. The bottleneck is rarely the NAPR registration itself. Pharmaceutical-specific licensing from Georgia's regulatory authority is a separate process and adds materially to the timeline: a wholesale import licence can take several weeks to a few months depending on the completeness of the premises and personnel documentation, and product registration for a new pharmaceutical product typically requires six to eighteen months. Foreign companies should structure their market entry timeline around the regulatory licensing process, not the entity registration process.
Q: What documents does a foreign parent company need to open a branch in Georgia?
A: The core document set for branch registration includes: the foreign parent company's certificate of incorporation (or equivalent founding document), the parent's articles of association or charter, a corporate resolution authorising the establishment of the branch and appointing the branch's authorised representative, proof of a registered address in Georgia, and identification documents for the authorised representative. All foreign-language documents must be translated into Georgian by a certified translator and, depending on the home jurisdiction, apostilled or otherwise legalised. For documents from jurisdictions that are parties to the Hague Apostille Convention, apostillation is the standard route. The complete package should be assembled before submission; incomplete applications are returned and restart the timeline.
Q: What happens if a representative office begins conducting commercial pharmaceutical sales?
A: A representative office that conducts commercial activity — including concluding sales contracts, issuing invoices, or receiving payment for pharmaceutical products — operates outside the legally permitted scope of its registration. The Revenue Service of the Ministry of Finance may reclassify the activity as that of a permanent establishment of the foreign parent, with the consequence that the income generated becomes subject to Georgian corporate income tax and, potentially, VAT. In addition, conducting wholesale pharmaceutical activity without the required licence exposes both the representative office and the foreign parent to administrative liability under Georgian pharmaceutical regulation, which can include fines and the suspension of activity. Companies that find themselves in this position should seek legal advice promptly and consider regularising their structure by registering an LLC with the appropriate pharmaceutical licence.
Vetrov & Partners is a Russian boutique law firm established in 2009, recognised by Pravo-300 — Russia's principal legal directory — for eight consecutive years, and listed as a trusted adviser by the German Consulate General in Novosibirsk.
The firm's market entry and cross-border advisory practice supports foreign companies and investors navigating the legal landscape of Russia and the post-Soviet region, including Georgia. For matters governed by Georgian law, the firm works in collaboration with trusted Georgian counsel, combining Russian-law expertise with regional structuring knowledge across the Caucasus and Central Asian corridor. With over 1,000 matters handled since inception, the team provides partner-level involvement on every engagement.
Enquiries: info@vetrovpartners.com | WhatsApp / Telegram: +7 (983) 510-38-76 | t.me/vitvetcom
[CTA: If you are evaluating pharmaceutical market entry structures in Georgia or a related jurisdiction, make an enquiry: info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]
— Nino Beridze Contributing Regional Analyst — Georgia, Vetrov & Partners vetrovpartners.com/contributions/
Nino Beridze is a Contributing Regional Analyst at Vetrov & Partners, focusing on Georgian company law, pharmaceutical regulation, and inbound market entry structuring for foreign investors. She collaborates with the firm's Russian-qualified team on cross-border mandates spanning the Russia–Georgia corridor.
This publication is provided for informational purposes only and does not constitute legal advice under Russian or any other applicable law. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Vetrov & Partners is a Russian-qualified law firm. For matters governed by foreign law or requiring local admission in another jurisdiction, we collaborate with trusted counsel in the relevant jurisdiction. For advice regarding your particular situation, please contact info@vetrovpartners.com.